NCT02723162View on ClinicalTrials.gov

Translational Neuropsychopharmacology Research of Nicotine Addiction

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

March 9, 2020

Study Completion Date

March 9, 2020

Conditions
Nicotine Dependence, Cigarettes
Interventions
DRUG

Varenicline (VRN)

VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.

DRUG

N-Acetylcysteine (NAC)

NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment

DRUG

Placebo

Matched placebo

Trial Locations (1)

29403

Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER

NCT02723162 - Translational Neuropsychopharmacology Research of Nicotine Addiction | Biotech Hunter | Biotech Hunter